A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
Abstract Introduction The main objective of this study was to examine discontinuation rates associated with delayed-release dimethyl fumarate (DMF) when used for the treatment of relapsing multiple sclerosis (MS) in a real-world, clinical practice setting. Methods Data were collected retrospectively...
Main Authors: | Michelle Allan, Lindsay Grant |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-12-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-019-00174-3 |
Similar Items
-
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01) -
Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
by: Raed Alroughani, et al.
Published: (2021-01-01) -
Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01) -
A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
by: Takahiko Saida, et al.
Published: (2019-01-01) -
Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
by: Narapureddy B, et al.
Published: (2019-10-01)